Abstract
Abstract The canonical arm of NF-κB signaling is well studied in Inflammatory Bowel Disease (IBD) while its noncanonical counterpart has yet to be fully defined. The activation of the noncanonical pathway initiates the nuclear transcription of chemokines associated with chronic inflammation and other diverse immunological processes. Infliximab is an effective anti-TNF treatment that reduces inflammation in IBD, yet a significant percentage of patients are unresponsive or lose responsiveness. Here, we show that noncanonical NF-κB signaling has more relevant implications on IBD and its expression levels correlate to infliximab responsiveness. Our study evaluated noncanonical NF-κB signaling in 27 IBD patient and 9 non-IBD control patient tissue biopsies. Data from these studies were analyzed using bioinformatics to predict its influence on cellular pathways. Genes related to the noncanonical NF-κB pathway were significantly upregulated in IBD lesions compared to healthy tissue. IBD patients that positively respond to infliximab had significantly decreased expression levels compared to nonresponsive patients. These results suggest infliximab, when effective, decreases noncanonical signaling to lessen inflammation. Through targeting in part, the noncanonical NF-κB pathway has prominent emerging roles in IBD pathobiology and is an indicator for improving drug efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.